Résultats de recherche
Il y a 23 heures · SARASOTA, FL - Silo Pharma, Inc. (NASDAQ:SILO), a biopharmaceutical company specializing in novel therapies, has announced an exclusive licensing deal with Columbia University to develop and market its primary drug candidate, SPC-15, for stress-related disorders and PTSD. The agreement grants Silo the global rights to advance SPC-15, which is ...
Il y a 23 heures · Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders ...
Il y a 23 heures · Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders ...
Il y a 5 heures · Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (“MS”). Silo’s research and development programs are conducted through collaborations with universities and independent laboratories.
Il y a 10 heures · Extensive Issued and Pending IP Patent Applications Acquired with License Agreement SARASOTA, FL, July 08, 2024 -- Silo Pharma, Inc. , a developmental stage biopharmaceutical company focused on...
Il y a 5 heures · InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters License Agreement with Columbia University for Lead Candidate Targeting PTSD, Stress-Induced Anxiety Disorders
Il y a 23 heures · Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders
